Compare MPLX LP (MPLX) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MPLX LP vs Vertex Pharmaceuticals Incorporated — how do they compare? MPLX LP trades at $59.3 (market cap $59.51B), while Vertex Pharmaceuticals Incorporated trades at $528.01 (market cap $132.79B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 2.2× MPLX LP's market cap, and MPLX LP pays a 7.34% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| MPLX | VRTX | |
|---|---|---|
Market Cap | $59.51B | $132.79B |
Sector | Technology | Health |
52-Week High | $60.51 | $529.65 |
52-Week Low | $47.80 | $376.62 |
Enterprise Value | $84.62B | $126.92B |
Dividend Yield | 7.34% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MPLX trades at $58.85, down 2.6% today, with a bullish technical outlook supported by moving averages and strong institutional support. The company maintains robust profitability with 40.45% net income margin and 33.95% ROE, though recent quarters showed mixed earnings performance with two misses. Recent news highlights MPLX's $2.25 billion senior notes offering and solid Q2 2026 results with 5% EBITDA growth.
The stock presents a compelling income opportunity with a 7.3% yield and analyst consensus price target of $61.50 (4.5% upside). Key risks include execution challenges from higher capital spending and leverage concerns, while growth projects in natural gas and NGL services provide multi-year visibility.
Vertex Pharmaceuticals (VRTX) trades at $496.07, up 2.49% on the day, with a bullish technical signal from moving averages and strong institutional support. The company reported Q2 2026 revenue of $3.3 billion, beating estimates, and raised its full-year sales outlook, driven by cystic fibrosis treatments and newer products like CASGEVY. Financials show robust profitability with a 35% net income margin and positive cash flow trends, though recent EPS results have been mixed.
Outlook remains positive with an 84% analyst buy rating and a $534.25 consensus price target, implying upside. Key risks include execution on new product launches and competitive pressures, but solid fundamentals and raised guidance support a constructive view for investors seeking growth in biopharma.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About MPLX LP
MPLX LP is a Master Limited Partnership (MLP) formed by Marathon Petroleum Corporation (MPC). It is a diversified, growth-oriented company primarily engaged in the gathering, processing, and transportation of natural gas and natural gas liquids (NGLs), as well as the transportation, storage, and distribution of crude oil and refined petroleum products. MPLX owns and operates a network of midstream energy infrastructure assets, providing essential services to the energy industry across the United States.
Read more on MPLX →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
